Barclays Maintains Overweight on MBX Biosciences, Raises Price Target to $70
Benzinga Newsdesk 5 months ago
NewsPrice TargetAnalyst Ratings
Barclays analyst Eliana Merle maintains MBX Biosciences (NASDAQ:MBX) with a Overweight and raises the price target from $66 to $70.
Barclays analyst Eliana Merle maintains MBX Biosciences (NASDAQ:MBX) with a Overweight and raises the price target from $66 to $70.